One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2167-2172

  Tandstad, T ^a   Stahl O ^b   Hakansson U ^b   Dahl, O ^c,d   Haugnes, H S ^e,f   Klepp, O H ^g   Langberg, C W ^h   Laurell, A ⁱ   Oldenburg, J ^h   Solberg, A ^a   Soderstrom K ^j   Cavallin Stah E ^k   Stierner, U ^k   Wahlquist, R ^h   Wall, N ^l   Cohn Cedermark, G ^m,n  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

^f UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^g Alesund Hospital   (Norway)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^j UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l LINKÖPING UNIVERSITY   (Sweden)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Adjuvant chemotherapy; Nonseminoma; Testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NORWEGIAN (PEOPLE); OVERALL SURVIVAL; PRIORITY JOURNAL; SWEDE (PEOPLE); TESTIS NONSEMINOMA CANCER; TUMOR RECURRENCE; ADJUVANT CHEMOTHERAPY; KAPLAN MEIER METHOD; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; TESTICULAR NEOPLASMS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ETOPOSIDE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TESTICULAR NEOPLASMS;

EID: 84918827743     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu375     Document Type: Article

References (27)

1. Nationell rapport för Testikkelcancerregistret. Seminom och Non-seminom 2012: Regionalt cancercentrum Stockholm/Gotland og Syd 2013.
2. de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol 2006; 24: 5482-5492.
3. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003; 111: 76-83; discussion 83-75.
4. Kollmannsberger C, Moore C, Chi KN et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010; 21: 1296-1301.
5. Sturgeon JF, Moore MJ, Kakiashvili DM et al. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's Experience. Eur Urol 2011; 59: 556-562.
6. Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14: 1106-1113.
7. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128.
8. Cullen M. Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours. Ann Oncol 2012; 23(Suppl 10): x342-x348.
9. Bohlen D, Borner M, Sonntag RW et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999; 161: 1148-1152.
10. Albers P, Siener R, Krege S et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966-2972.
11. Nichols CR, Kollmannsberger C. Vox populi: using community-based studies to determine best management of early-stage nonseminoma. J Clin Oncol 2009; 27: 2114-2116.
12. Beyer J, Albers P, Altena R et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2013; 24: 878-888.
13. Albers P, Albrecht W, Algaba F et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011; 60: 304-319.
14. Wood L, Kollmannsberger C, Jewett M et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 2010; 4: e19-e38.
15. Tandstad T, Cohn-Cedermark G, Dahl O et al. Long-term follow-up after riskadapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol 2010; 21: 1858-1863.
16. Olofsson SE, Tandstad T, Jerkeman M et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 2011; 29: 2032-2039.
17. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
18. Westermann DH, Schefer H, Thalmann GN et al. Long-term follow-up results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 2008; 179: 163-166.
19. Gilbert DC, Norman AR, Nicholl J et al. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int 2006; 98: 67-69.
20. Haugnes HS, Bosl GJ, Boer H et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30: 3752-3763.
21. Brydoy M, Fossa SD, Klepp O et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 2010; 58: 134-140.
22. Skoogh J, Steineck G, Stierner U et al. Long-term cognitive function among testicular cancer survivors treated with chemotherapy. J Clin Oncol 2008; 26 (suppl); abstr 5035.
23. Stahl O, Eberhard J, Cavallin-Stahl E et al. Sperm DNA integrity in cancer patients: the effect of disease and treatment. Int J Androl 2009; 32: 695-703.
24. Brydoy M, Fossa SD, Klepp O et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97: 1580-1588.
25. Haugnes HS, Aass N, Fossa SD et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27: 2779-2786.
26. Haugnes HS, Aass N, Fossa SD et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-248.
27. Nichols CR, Roth B, Albers P et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 2013; 31: 3490-3493.